ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

O’Conor Names DCCP Director, Says He’ll Push Development Of NCI’s Efforts In Epidemiology

April 28, 1978

Scientific Community Rallies To Support DeVita; Immediate Suspension Of Straus’ Grant Considered

June 12, 1981

Reports of SPOREs cut Premature, Broder Says, Wait for Peer Review

March 13, 1992

Oxaliplatin Regimen May Beat Standard For Advanced Colorectal Cancer, NCI Says

April 26, 2002

Science Policcy: HHS Concludes NIH May und Human Stem Cell REsearch

January 22, 1999

ASCO President David Johnson to oncologists: It’s time to “reconnect to our patients” and “recommit to our profession.” Horning outlines priorities.

May 20, 2005